DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice

Yu Ping Shi, Paul Naik, William F. Dietrich, Joe Gray, Douglas Hanahan, Daniel Pinkel

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Comparative genomic hybridization (CGH) provides a method of surveying the entire tumor genome for regional variations in DNA sequence copy number. Such variations, if found recurrently, may indicate the locations of genes that contribute to tumor development through upregulation of oncogenes (copy number increase), inactivation of tumor-suppressor genes (copy number decrease), or changes in the level of expression through gene dosage effects. Thus, CGH is a powerful tool for screening for new cancer genes. Although CGH is widely applied to human genome analysis, application to the mouse is only beginning. The present study is designed to compare results obtained by CGH with those obtained by other techniques used for analysis of the murine genome. We report CGH analysis of several control cell lines with cytogenetically established regional copy number changes, as well as analysis of 16 primary insulinomas, four tumor-derived ceil lines, and three hyperplasia-derived cell lines from transgenic mice expressing the SV40 large T antigen under control of the rat insulin promoter. Loss of heterozygosity (LOH) on chromosomes 9 and 16 had previously been found to be frequent in primary insulinomas, and specimens were selected for the present study based on the LOH status of these chromosomes. We found complete concordance of the CGH results with the cytogenetically described copy number changes in the control cell lines and with the LOH on chromosomes 9 and 16 in the tumors. Thus, CGH can provide accurate data in murine systems, and it reveals that the LOH in these islet cell tumors most frequently results from deletion of one of the alleles.

Original languageEnglish (US)
Pages (from-to)104-111
Number of pages8
JournalGenes Chromosomes and Cancer
Volume19
Issue number2
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Islet Cell Carcinoma
DNA Copy Number Variations
Comparative Genomic Hybridization
Loss of Heterozygosity
Transgenic Mice
Chromosomes, Human, Pair 16
Chromosomes, Human, Pair 9
Insulinoma
Gene Dosage
Cell Line
Neoplasms
Genome
Islet Cell Adenoma
Polyomavirus Transforming Antigens
Neoplasm Genes
Viral Tumor Antigens
Human Genome
Tumor Suppressor Genes
Oncogenes
Hyperplasia

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice. / Shi, Yu Ping; Naik, Paul; Dietrich, William F.; Gray, Joe; Hanahan, Douglas; Pinkel, Daniel.

In: Genes Chromosomes and Cancer, Vol. 19, No. 2, 1997, p. 104-111.

Research output: Contribution to journalArticle

Shi, Yu Ping ; Naik, Paul ; Dietrich, William F. ; Gray, Joe ; Hanahan, Douglas ; Pinkel, Daniel. / DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice. In: Genes Chromosomes and Cancer. 1997 ; Vol. 19, No. 2. pp. 104-111.
@article{62ab2e889bfd43caa52faca609eb81b2,
title = "DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice",
abstract = "Comparative genomic hybridization (CGH) provides a method of surveying the entire tumor genome for regional variations in DNA sequence copy number. Such variations, if found recurrently, may indicate the locations of genes that contribute to tumor development through upregulation of oncogenes (copy number increase), inactivation of tumor-suppressor genes (copy number decrease), or changes in the level of expression through gene dosage effects. Thus, CGH is a powerful tool for screening for new cancer genes. Although CGH is widely applied to human genome analysis, application to the mouse is only beginning. The present study is designed to compare results obtained by CGH with those obtained by other techniques used for analysis of the murine genome. We report CGH analysis of several control cell lines with cytogenetically established regional copy number changes, as well as analysis of 16 primary insulinomas, four tumor-derived ceil lines, and three hyperplasia-derived cell lines from transgenic mice expressing the SV40 large T antigen under control of the rat insulin promoter. Loss of heterozygosity (LOH) on chromosomes 9 and 16 had previously been found to be frequent in primary insulinomas, and specimens were selected for the present study based on the LOH status of these chromosomes. We found complete concordance of the CGH results with the cytogenetically described copy number changes in the control cell lines and with the LOH on chromosomes 9 and 16 in the tumors. Thus, CGH can provide accurate data in murine systems, and it reveals that the LOH in these islet cell tumors most frequently results from deletion of one of the alleles.",
author = "Shi, {Yu Ping} and Paul Naik and Dietrich, {William F.} and Joe Gray and Douglas Hanahan and Daniel Pinkel",
year = "1997",
doi = "10.1002/(SICI)1098-2264(199706)19:2<104::AID-GCC6>3.0.CO;2-2",
language = "English (US)",
volume = "19",
pages = "104--111",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice

AU - Shi, Yu Ping

AU - Naik, Paul

AU - Dietrich, William F.

AU - Gray, Joe

AU - Hanahan, Douglas

AU - Pinkel, Daniel

PY - 1997

Y1 - 1997

N2 - Comparative genomic hybridization (CGH) provides a method of surveying the entire tumor genome for regional variations in DNA sequence copy number. Such variations, if found recurrently, may indicate the locations of genes that contribute to tumor development through upregulation of oncogenes (copy number increase), inactivation of tumor-suppressor genes (copy number decrease), or changes in the level of expression through gene dosage effects. Thus, CGH is a powerful tool for screening for new cancer genes. Although CGH is widely applied to human genome analysis, application to the mouse is only beginning. The present study is designed to compare results obtained by CGH with those obtained by other techniques used for analysis of the murine genome. We report CGH analysis of several control cell lines with cytogenetically established regional copy number changes, as well as analysis of 16 primary insulinomas, four tumor-derived ceil lines, and three hyperplasia-derived cell lines from transgenic mice expressing the SV40 large T antigen under control of the rat insulin promoter. Loss of heterozygosity (LOH) on chromosomes 9 and 16 had previously been found to be frequent in primary insulinomas, and specimens were selected for the present study based on the LOH status of these chromosomes. We found complete concordance of the CGH results with the cytogenetically described copy number changes in the control cell lines and with the LOH on chromosomes 9 and 16 in the tumors. Thus, CGH can provide accurate data in murine systems, and it reveals that the LOH in these islet cell tumors most frequently results from deletion of one of the alleles.

AB - Comparative genomic hybridization (CGH) provides a method of surveying the entire tumor genome for regional variations in DNA sequence copy number. Such variations, if found recurrently, may indicate the locations of genes that contribute to tumor development through upregulation of oncogenes (copy number increase), inactivation of tumor-suppressor genes (copy number decrease), or changes in the level of expression through gene dosage effects. Thus, CGH is a powerful tool for screening for new cancer genes. Although CGH is widely applied to human genome analysis, application to the mouse is only beginning. The present study is designed to compare results obtained by CGH with those obtained by other techniques used for analysis of the murine genome. We report CGH analysis of several control cell lines with cytogenetically established regional copy number changes, as well as analysis of 16 primary insulinomas, four tumor-derived ceil lines, and three hyperplasia-derived cell lines from transgenic mice expressing the SV40 large T antigen under control of the rat insulin promoter. Loss of heterozygosity (LOH) on chromosomes 9 and 16 had previously been found to be frequent in primary insulinomas, and specimens were selected for the present study based on the LOH status of these chromosomes. We found complete concordance of the CGH results with the cytogenetically described copy number changes in the control cell lines and with the LOH on chromosomes 9 and 16 in the tumors. Thus, CGH can provide accurate data in murine systems, and it reveals that the LOH in these islet cell tumors most frequently results from deletion of one of the alleles.

UR - http://www.scopus.com/inward/record.url?scp=0006429025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0006429025&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2264(199706)19:2<104::AID-GCC6>3.0.CO;2-2

DO - 10.1002/(SICI)1098-2264(199706)19:2<104::AID-GCC6>3.0.CO;2-2

M3 - Article

C2 - 9172001

AN - SCOPUS:0006429025

VL - 19

SP - 104

EP - 111

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 2

ER -